Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Investor Presentation (August 2025)
18 slides from Avita Medical's investor presentation, Aug 14, 2025
Slide 1: Transforming Acute Wound Care
For personal use only Transforming Acute Wound Care Jim Corbett, CEO, AVITA Medical Australia Investor Presentation August, 2025
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results, perform
Slide 3: We Are a Leading Therapeutic Acute Wound Care Company
We Are a Leading Therapeutic Acute Wound Care Company For personal use only Mission: Impact: Transform acute Optimize wound wound care healing, resulting in less hospital time and faster patient recovery 3
Slide 4: Integrated Next Generation Portfolio
For personal use only Integrated Next Generation Portfolio 4
Slide 5: We Provide Next Generation Therapies Across the Continuum of Wound Care
We Provide Next Generation Therapies Across the Continuum of Wound Care… Same wound, same patient, same doctor, same hospital; same AVITA Medical portfolio For personal use only WOUND BED EPIDERMAL WOUND SITE DERMAL MATRIX TEMPORIZING REPLACEMENT COVERAGE Next-generation Collagen-based dermal First-
Slide 6: … and Every Layer of the Wound
… and Every Layer of the Wound AVITA Portfolio Fit For personal use only Partial-Thickness Deep Partial-Thickness Full-Thickness Wound Wound Wound Patient Reach & Per-Case Revenue Opportunity Broad; Broad; Broad; Up to US$8,000 Up to US$21,000 Up to US$57,000 6 Example is based upon a 10-20% Total B
Slide 7: Strengthening the Clinical Case: Trials Enrolling
Strengthening the Clinical Case: Trials Enrolling Cohealyx I PermeaDerm I For personal use only Evaluate ability to advance Evaluate clinical effectiveness wound bed preparation and and safety in wound bed readiness for closure. preparation compared to Allograft. Primary Endpoint Primary Endpoint T
Slide 8: Treating Patients in a Large $3.5B+ Acute Wound Care Opportunity
Treating Patients in a Large $3.5B+ Acute Wound Care Opportunity For personal use only 2025 Long-Term BURN & TRAUMA, MULTI- BURN & TRAUMA, MULTI- PRODUCT PRODUCT $3.5B >$3.5B TAM (U.S.) TAM Scaling TAM through Portfolio 1 Expansion and Efficient Execution Multi-Product Strategy 2 Enables Case-Level
Slide 9: Reducing "Length of Stay"
For personal use only Reducing “Length of Stay”
Slide 10: RECELL: 36% Reduction in Length of Stay: This Changes Everything
RECELL: 36% Reduction in Length of Stay: This Changes Everything Analysis presented at the British RECELL decreases hospital stays by approximately 36% For personal use only in the largest burn center real-world analysis to date. Burn Association (BBA) annual Number of hospital days for deep partial
Slide 11: Cohealyx Prepares Grafts in Days, Not Weeks
Cohealyx Prepares Grafts in Days, Not Weeks Competitor A Competitor B Pre-CLINICAL Skin graft take1 use only Cohealyx wound beds were ready for grafting at Day 71, with 0 Day consistent skin graft take compared to other dermal matrices 120 * 7 Days Skin Graft Take % (Day 7) 100 ForPrior7personal 97%
Slide 12: Preclinical Superiority Backed by Real-World Results
Preclinical Superiority Backed by Real-World Results First peer-reviewed clinical study For personal use only showed fewer “days to graft” than Accelerating healing for complex wounds: How Cohealyx advances readiness to autografting competition Ohio State case: A 48-year-old man with comorbidities C
Slide 13: Potential Hospital Savings From Reduced Length of Stay
Potential Hospital Savings From Reduced Length of Stay Early grafting > Reduced LOS > Hospital Savings Potential hospital cost savings from reduced length of stay* For personal use only Early grafting may lead to meaningful reductions in length of stay and overall hospital costs1 Typical daily inpat
Slide 14: Financial Update and Outlook
For personal use only Financial Update and Outlook
Slide 15: RECELL Demand Impacted by CMS Reimbursement Gap, Recovery Expected in Q3
RECELL Demand Impacted by Centers for Medicare & Medicaid Services (CMS) Reimbursement Gap, Recovery Expected in Q3 For personal use only Unpaid Provider Claims Impact on RECELL Resolution • In January, CMS introduced This uncertainty impacted Q3 breakthrough: Multiple MACs new CPT codes for RECELL.
Slide 16: AVITA Full-Year Commercial Revenue Forecast and Financial Guidance
AVITA Full-Year Commercial Revenue Forecast and Financial Guidance Metric Previous guidance Updated guidance For personal use only Full-year 2025 revenue $100m to $106m $76m to $81m Growth vs. FY2024 ~55% to 65% ~19% to 27% Cash flow break-even 2H 2025 Q2 2026 GAAP profitability Q4 2025 Q3 2026 Mome
Slide 17: Takeaways
Takeaways For personal use only AVITA is redefining what’s possible in wound healing Clear focus on executing our strategy AVITA’s financial forecast With resolution in the Compelling reduction in updated to reflect backlog of claims length of stay (LOS) is a recovery trajectory and underway, full d
Slide 18: For personal use only
For personal use only